Fed’s Powell opens door to potential rate cuts at Jackson Hole
Michael A. Pisetsky, the Senior Vice President and Chief Legal Officer of SI-BONE, Inc. (NASDAQ:SIBN), recently sold shares of the company’s common stock valued at approximately $44,219. The transactions, which took place on April 2, 2025, involved the sale of a total of 3,128 shares at prices ranging from $13.86 to $14.1742 per share. The medical device company, currently valued at $571 million, has seen its stock decline 11.7% over the past year, though InvestingPro analysis indicates the stock is in oversold territory.
These sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units, as noted in the filing. Following these transactions, Pisetsky holds 244,878 shares of SI-BONE, including 157,982 shares issuable upon the settlement of restricted stock units. While the company maintains strong financial health with a current ratio of 7.66 and more cash than debt on its balance sheet, analysts have set price targets ranging from $19 to $32. For deeper insights into insider trading patterns and comprehensive financial analysis, check out the detailed InvestingPro Research Report, which provides expert analysis on what really matters for SI-BONE’s future prospects.
In other recent news, SI-BONE Inc. reported its fourth-quarter 2024 financial results, showcasing a revenue of $49 million, which exceeded analyst expectations and marked a 26% year-over-year increase. The U.S. market was a significant contributor, with a 28% rise in revenue. The company also reported an adjusted EBITDA of $1.9 million, highlighting improved financial management and operational efficiency. Looking forward, SI-BONE has projected its 2025 revenue to range between $193.5 million and $195.5 million, indicating an anticipated growth of 16% to 17%.
Cantor Fitzgerald reaffirmed its Overweight rating on SI-BONE, maintaining a price target of $25, while Needham raised its price target from $20 to $24, both firms citing strong financial guidance and positive market positioning as key factors. The company has seen a notable increase in its active surgeon base, with approximately 1,400 U.S. surgeons engaged with its products, representing a 23% growth from the previous year. Additionally, SI-BONE’s focus on innovation has been well-received, with the successful launch of three key products in 2024 contributing to its growth trajectory.
The company’s strategic initiatives, including the expansion of its sales force and the introduction of new products, are expected to continue driving demand and revenue growth. Analysts from Needham expressed confidence in SI-BONE’s ability to exceed revenue expectations, potentially leading to enhanced profitability. The firm’s positive outlook is further supported by the company’s strong cash position, with $150 million in cash and marketable securities at the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.